Grail released large‑study results indicating its multi‑cancer blood test Galleri improved positive predictive value (PPV) in the PATHFINDER program, increasing the proportion of positive screens that correlate with actual cancer diagnoses. Company‑reported metrics from PATHFINDER 2 show higher PPV and modest sensitivity gains when follow‑up intervals are extended and adjudication is refined. STAT and company briefings noted the PATHFINDER datasets enrolled tens of thousands of adults and that Grail adjusted algorithms and clinical workflows to reduce false positives. The company said the new performance metrics strengthen its case for broader clinical deployment and underpin a pending regulatory filing. Independent experts at the meeting flagged remaining questions about population screening impact and health‑system implementation. Investors and payers will watch regulatory feedback closely; improvements in PPV may influence reimbursement and clinical uptake for population screening. Galleri is a multi‑cancer early‑detection blood test aimed at identifying signals from multiple tumor types before clinical symptoms appear.